Financial Analysis: Monopar Therapeutics (NASDAQ:MNPR) & Zoetis (NYSE:ZTS)

Monopar Therapeutics (NASDAQ:MNPRGet Free Report) and Zoetis (NYSE:ZTSGet Free Report) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, dividends, valuation and institutional ownership.

Analyst Ratings

This is a summary of current recommendations for Monopar Therapeutics and Zoetis, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Monopar Therapeutics 0 0 2 0 3.00
Zoetis 0 0 7 0 3.00

Monopar Therapeutics currently has a consensus target price of $2.00, suggesting a potential upside of 177.78%. Zoetis has a consensus target price of $211.75, suggesting a potential upside of 21.13%. Given Monopar Therapeutics’ higher possible upside, equities analysts plainly believe Monopar Therapeutics is more favorable than Zoetis.

Valuation & Earnings

This table compares Monopar Therapeutics and Zoetis’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Monopar Therapeutics N/A N/A -$8.40 million ($0.52) -1.38
Zoetis $8.54 billion 9.34 $2.34 billion $5.19 33.68

Zoetis has higher revenue and earnings than Monopar Therapeutics. Monopar Therapeutics is trading at a lower price-to-earnings ratio than Zoetis, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Monopar Therapeutics and Zoetis’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Monopar Therapeutics N/A -110.42% -86.33%
Zoetis 27.38% 50.34% 17.59%

Risk and Volatility

Monopar Therapeutics has a beta of 1.18, indicating that its stock price is 18% more volatile than the S&P 500. Comparatively, Zoetis has a beta of 0.86, indicating that its stock price is 14% less volatile than the S&P 500.

Insider and Institutional Ownership

1.8% of Monopar Therapeutics shares are owned by institutional investors. Comparatively, 92.8% of Zoetis shares are owned by institutional investors. 41.6% of Monopar Therapeutics shares are owned by company insiders. Comparatively, 0.2% of Zoetis shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Zoetis beats Monopar Therapeutics on 9 of the 12 factors compared between the two stocks.

About Monopar Therapeutics

(Get Free Report)

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo EspaƱol de InvestigaciĆ³n en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.

About Zoetis

(Get Free Report)

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics, and medicated feed additives. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was founded in 1952 and is headquartered in Parsippany, New Jersey.

Receive News & Ratings for Monopar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Monopar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.